<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35162978</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23031047</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disorder. There is no cure and current treatments fail to slow the progression of the disease. Epigenetic modulation in the acetylation state of NF-kB RelA and the histone 3 (H3) protein, involved in the development of neurodegeneration, is a drugable target for the class-I histone deacetylases (HDAC) inhibitors, entinostat or valproate, and the AMP-activated kinase (AMPK)-sirtuin 1 pathway activator, resveratrol. In this study, we demonstrated that the combination of valproate and resveratrol can restore the normal acetylation state of RelA in the SOD1(G93A) murine model of ALS, in order to obtain the neuroprotective form of NF-kB. We also investigated the sexually dimorphic development of the disease, as well as the sex-sensibility to the treatment administered. We showed that the combined drugs, which rescued AMPK activation, RelA and the histone 3 acetylation state, reduced the motor deficit and the disease pathology associated with motor neuron loss and microglial reactivity, Brain-Derived Neurotrophic Factor (BDNF) and B-cell lymphoma-extra large (Bcl-xL) level decline. Specifically, vehicle-administered males showed earlier onset and slower progression of the disease when compared to females. The treatment, administered at 50 days of life, postponed the time of onset in the male by 22 days, but not in a significant way in females. Nevertheless, in females, the drugs significantly reduced symptom severity of the later phase of the disease and prolonged the mice's survival. Only minor beneficial effects were produced in the latter stage in males. Overall, this study shows a beneficial and sexually dimorphic response to valproate and resveratrol treatment in ALS mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bankole</LastName><ForeName>Oluwamolakun</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-3374-0614</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scambi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrella</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0365-5144</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, 25123 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muccilli</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8060-6528</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonafede</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turano</LastName><ForeName>Ermanna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzi</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, 25123 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariotti</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B34I19002690003</GrantID><Agency>Fondazione Cariverona</Agency><Country/></Grant><Grant><GrantID>754345</GrantID><Agency>European Union</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.31</RegistryNumber><NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C470545">Sirt1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q369O8926L</RegistryNumber><NameOfSubstance UI="D000077185">Resveratrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077185" MajorTopicYN="N">Resveratrol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">epigenetics</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">resveratrol</Keyword><Keyword MajorTopicYN="N">valproate</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35162978</ArticleId><ArticleId IdType="pmc">PMC8835218</ArticleId><ArticleId IdType="doi">10.3390/ijms23031047</ArticleId><ArticleId IdType="pii">ijms23031047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E., Bonetto V., Soraru G., Martinelli I., Parchi P., Liguori R., Mandrioli J. Neurofilaments in motor neuron disorders: Towards promising diagnostic and prognostic biomarkers. Mol. Neurodegener. 2020;15:58. doi: 10.1186/s13024-020-00406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00406-3</ArticleId><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsultan A.A., Waller R., Heath P.R., Kirby J. The genetics of amyotrophic lateral sclerosis: Current insights. Degener. Neurol. Neuromuscul. Dis. 2016;6:49&#x2013;64. doi: 10.2147/DNND.S84956.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S84956</ArticleId><ArticleId IdType="pmc">PMC6053097</ArticleId><ArticleId IdType="pubmed">30050368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vegeto E., Villa A., Della Torre S., Crippa V., Rusmini P., Cristofani R., Galbiati M., Maggi A., Poletti A. The Role of Sex and Sex Hormones in Neurodegenerative Diseases. Endocr. Rev. 2020;41:273&#x2013;319. doi: 10.1210/endrev/bnz005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnz005</ArticleId><ArticleId IdType="pmc">PMC7156855</ArticleId><ArticleId IdType="pubmed">31544208</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl S.R., Halicek M.T., Mitchell C.S. Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis. J. Neuromuscul. Dis. 2015;2:137&#x2013;150. doi: 10.3233/JND-140068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-140068</ArticleId><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos D., Ramirez-Nunez O., Granado-Serrano A.B., Torres P., Ayala V., Moiseeva V., Povedano M., Ferrer I., Pamplona R., Portero-Otin M., et al. Early and gender-specific differences in spinal cord mitochondrial function and oxidative stress markers in a mouse model of ALS. Acta Neuropathol. Commun. 2016;4:3. doi: 10.1186/s40478-015-0271-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0271-6</ArticleId><ArticleId IdType="pmc">PMC4711180</ArticleId><ArticleId IdType="pubmed">26757991</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese F., Sartori A., Verriello L., Ros S., Passadore P., Manganotti P., Barbone F., Pisa F.E. Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002-2014: A retrospective population-based study. Amyotroph. Lateral Scler. Front. Degener. 2019;20:90&#x2013;99. doi: 10.1080/21678421.2018.1511732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1511732</ArticleId><ArticleId IdType="pubmed">30430867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun K.Y., Park J., Oh K.W., Kim E.M., Bae J.S., Kim I., Kim S.H. Epidemiology of ALS in Korea using nationwide big data. J. Neurol. Neurosurg. Psychiatry. 2019;90:395&#x2013;403. doi: 10.1136/jnnp-2018-318974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318974</ArticleId><ArticleId IdType="pmc">PMC6581156</ArticleId><ArticleId IdType="pubmed">30409890</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Guennoc A.M., Veyrat-Durebex C., Gordon P.H., Andres C.R., Camu W., Corcia P. Amyotrophic lateral sclerosis: A hormonal condition? Amyotroph. Lateral Scler. 2012;13:585&#x2013;588. doi: 10.3109/17482968.2012.706303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.706303</ArticleId><ArticleId IdType="pubmed">22873563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R., Mariotti R. ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Front. Cell. Neurosci. 2017;11:80. doi: 10.3389/fncel.2017.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00080</ArticleId><ArticleId IdType="pmc">PMC5359305</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.L., La Spada A.R. Senataxin, A Novel Helicase at the Interface of RNA Transcriptome Regulation and Neurobiology: From Normal Function to Pathological Roles in Motor Neuron Disease and Cerebellar Degeneration. Adv. Neurobiol. 2018;20:265&#x2013;281. doi: 10.1007/978-3-319-89689-2_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-89689-2_10</ArticleId><ArticleId IdType="pubmed">29916023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibeagha-Awemu E.M., Zhao X. Epigenetic marks: Regulators of livestock phenotypes and conceivable sources of missing variation in livestock improvement programs. Front. Genet. 2015;6:302. doi: 10.3389/fgene.2015.00302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2015.00302</ArticleId><ArticleId IdType="pmc">PMC4585011</ArticleId><ArticleId IdType="pubmed">26442116</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X., Figueroa-Romero C., Sakowski S.A., Goutman S.A., Feldman E.L. Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol. 2015;11:266&#x2013;279. doi: 10.1038/nrneurol.2015.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil V.V., Katzman R.B., Petrucelli L. ALS and FTD: An epigenetic perspective. Acta Neuropathol. 2016;132:487&#x2013;502. doi: 10.1007/s00401-016-1587-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1587-4</ArticleId><ArticleId IdType="pmc">PMC5138862</ArticleId><ArticleId IdType="pubmed">27282474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X.J., Seto E. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26:5310&#x2013;5318. doi: 10.1038/sj.onc.1210599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1210599</ArticleId><ArticleId IdType="pubmed">17694074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresselhaus E.C., Meffert M.K. Cellular Specificity of NF-kappaB Function in the Nervous System. Front. Immunol. 2019;10:1043. doi: 10.3389/fimmu.2019.01043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01043</ArticleId><ArticleId IdType="pmc">PMC6520659</ArticleId><ArticleId IdType="pubmed">31143184</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A., Bubacco L., Longhena F., Parrella E., Faustini G., Porrini V., Bono F., Missale C., Pizzi M. Nuclear Factor-kappaB Dysregulation and alpha-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson&#x2019;s Disease. Front. Aging Neurosci. 2020;12:68. doi: 10.3389/fnagi.2020.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00068</ArticleId><ArticleId IdType="pmc">PMC7105602</ArticleId><ArticleId IdType="pubmed">32265684</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan M., Lahiri D.K. Significance of NF-kappaB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer&#x2019;s disease and multiple sclerosis. Expert Opin. Ther. Targets. 2015;19:471&#x2013;487. doi: 10.1517/14728222.2014.989834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2014.989834</ArticleId><ArticleId IdType="pmc">PMC5873291</ArticleId><ArticleId IdType="pubmed">25652642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzillotta A., Porrini V., Bellucci A., Benarese M., Branca C., Parrella E., Spano P.F., Pizzi M. NF-kappaB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases. Front. Neurol. 2015;6:98. doi: 10.3389/fneur.2015.00098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00098</ArticleId><ArticleId IdType="pmc">PMC4438602</ArticleId><ArticleId IdType="pubmed">26042083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore T.D., Wolenski F.S. NF-kappaB: Where did it come from and why? Immunol. Rev. 2012;246:14&#x2013;35. doi: 10.1111/j.1600-065X.2012.01096.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2012.01096.x</ArticleId><ArticleId IdType="pubmed">22435545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzillotta A., Sarnico I., Ingrassia R., Boroni F., Branca C., Benarese M., Faraco G., Blasi F., Chiarugi A., Spano P., et al. The acetylation of RelA in Lys310 dictates the NF-kappaB-dependent response in post-ischemic injury. Cell Death Dis. 2010;1:e96. doi: 10.1038/cddis.2010.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2010.76</ArticleId><ArticleId IdType="pmc">PMC3032326</ArticleId><ArticleId IdType="pubmed">21368872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mincheva-Tasheva S., Soler R.M. NF-kappaB signaling pathways: Role in nervous system physiology and pathology. Neuroscientist. 2013;19:175&#x2013;194. doi: 10.1177/1073858412444007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858412444007</ArticleId><ArticleId IdType="pubmed">22785105</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe4;llstig E., McCabe B.D., Schneider B.L. The Links between ALS and NF-&#x3ba;B. Int. J. Mol. Sci. 2021;22:3875. doi: 10.3390/ijms22083875.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083875</ArticleId><ArticleId IdType="pmc">PMC8070122</ArticleId><ArticleId IdType="pubmed">33918092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikiz B., Alvarez M.J., Re D.B., Le Verche V., Politi K., Lotti F., Phani S., Pradhan R., Yu C., Croft G.F., et al. The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis. Cell Rep. 2015;12:335&#x2013;345. doi: 10.1016/j.celrep.2015.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.06.019</ArticleId><ArticleId IdType="pmc">PMC4646662</ArticleId><ArticleId IdType="pubmed">26146077</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T., Lautenschlager J., Weidemann L., Ruhmer J., Witte O.W., Grosskreutz J. Endoplasmic reticulum stress is accompanied by activation of NF-kappaB in amyotrophic lateral sclerosis. J. Neuroimmunol. 2014;270:29&#x2013;36. doi: 10.1016/j.jneuroim.2014.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2014.03.005</ArticleId><ArticleId IdType="pubmed">24666819</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X., Wang S., Qi Y., Wang X., Jiang H., Wang T., Yang Y., Wang Y., Zhang C., Feng H. Astrocyte elevated gene-1 is a novel regulator of astrogliosis and excitatory amino acid transporter-2 via interplaying with nuclear factor-kappaB signaling in astrocytes from amyotrophic lateral sclerosis mouse model with hSOD1(G93A) mutation. Mol. Cell Neurosci. 2018;90:1&#x2013;11. doi: 10.1016/j.mcn.2018.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.05.004</ArticleId><ArticleId IdType="pubmed">29777762</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A.E., Ferraiuolo L., Haidet-Phillips A.M., Schmelzer L., Braun L., Miranda C.J., Ladner K.J., Bevan A.K., Foust K.D., Godbout J.P., et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupre N., Petri S., Strong M., Kriz J., Julien J.P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M., Tanaka F., Sobue G. Gene expression profile of spinal ventral horn in ALS. Brain Nerve. 2007;59:1129&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">17969353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y.M., Yamamoto M., Kobayashi Y., Yoshihara T., Liang Y., Terao S., Takeuchi H., Ishigaki S., Katsuno M., Adachi H., et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005;57:236&#x2013;251. doi: 10.1002/ana.20379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20379</ArticleId><ArticleId IdType="pubmed">15668976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino L., Bonafede R., Scambi I., Parrella E., Pizzi M., Mariotti R. Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model. Sci. Rep. 2018;8:12875. doi: 10.1038/s41598-018-30659-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-30659-4</ArticleId><ArticleId IdType="pmc">PMC6110772</ArticleId><ArticleId IdType="pubmed">30150770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazo-Gomez R., Ramirez-Jarquin U.N., Tovar Y.R.L.B., Tapia R. Histone deacetylases and their role in motor neuron degeneration. Front. Cell Neurosci. 2013;7:243. doi: 10.3389/fncel.2013.00243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00243</ArticleId><ArticleId IdType="pmc">PMC3852234</ArticleId><ArticleId IdType="pubmed">24367290</ArticleId></ArticleIdList></Reference><Reference><Citation>Loscher W. Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16:669&#x2013;694. doi: 10.2165/00023210-200216100-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00023210-200216100-00003</ArticleId><ArticleId IdType="pubmed">12269861</ArticleId></ArticleIdList></Reference><Reference><Citation>Mello M.L.S. Sodium Valproate-Induced Chromatin Remodeling. Front. Cell Dev. Biol. 2021;9:645518. doi: 10.3389/fcell.2021.645518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.645518</ArticleId><ArticleId IdType="pmc">PMC8093769</ArticleId><ArticleId IdType="pubmed">33959607</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng H.L., Leng Y., Ma C.H., Zhang J., Ren M., Chuang D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008;155:567&#x2013;572. doi: 10.1016/j.neuroscience.2008.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.06.040</ArticleId><ArticleId IdType="pmc">PMC2709275</ArticleId><ArticleId IdType="pubmed">18640245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., del Valle J., Modol L., Martinez A., Granado-Serrano A.B., Ramirez-Nunez O., Pallas M., Portero-Otin M., Osta R., Navarro X. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics. 2014;11:419&#x2013;432. doi: 10.1007/s13311-013-0253-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0253-y</ArticleId><ArticleId IdType="pmc">PMC3996124</ArticleId><ArticleId IdType="pubmed">24414863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzillotta A., Pignataro G., Branca C., Cuomo O., Sarnico I., Benarese M., Annunziato L., Spano P., Pizzi M. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiol. Dis. 2013;49:177&#x2013;189. doi: 10.1016/j.nbd.2012.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.08.018</ArticleId><ArticleId IdType="pubmed">22971966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Lan F., Ido Y. AMPK and SIRT1: A long-standing partnership? Am. J. Physiol. Endocrinol. Metab. 2010;298:E751&#x2013;E760. doi: 10.1152/ajpendo.00745.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00745.2009</ArticleId><ArticleId IdType="pmc">PMC2853213</ArticleId><ArticleId IdType="pubmed">20103737</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani D., Esposito A., Criscitiello C., Mazzarella L., Locatelli M., Minchella I., Minucci S., Curigliano G. Entinostat for the treatment of breast cancer. Expert Opin. Investig. Drugs. 2017;26:965&#x2013;971. doi: 10.1080/13543784.2017.1353077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1353077</ArticleId><ArticleId IdType="pubmed">28718331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunsberger J.G., Fessler E.B., Wang Z., Elkahloun A.G., Chuang D.M. Post-insult valproic acid-regulated microRNAs: Potential targets for cerebral ischemia. Am. J. Transl. Res. 2012;4:316&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426385</ArticleId><ArticleId IdType="pubmed">22937209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Tsai L.K., Munasinghe J., Leng Y., Fessler E.B., Chibane F., Leeds P., Chuang D.M. Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke. 2012;43:2430&#x2013;2436. doi: 10.1161/STROKEAHA.112.652545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.652545</ArticleId><ArticleId IdType="pmc">PMC3429729</ArticleId><ArticleId IdType="pubmed">22811460</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauf A., Imran M., Suleria H.A.R., Ahmad B., Peters D.G., Mubarak M.S. A comprehensive review of the health perspectives of resveratrol. Food Funct. 2017;8:4284&#x2013;4305. doi: 10.1039/C7FO01300K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7FO01300K</ArticleId><ArticleId IdType="pubmed">29044265</ArticleId></ArticleIdList></Reference><Reference><Citation>Faggi L., Pignataro G., Parrella E., Porrini V., Vinciguerra A., Cepparulo P., Cuomo O., Lanzillotta A., Mota M., Benarese M., et al. Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke. Int. J. Mol. Sci. 2018;19:172. doi: 10.3390/ijms19010172.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010172</ArticleId><ArticleId IdType="pmc">PMC5796121</ArticleId><ArticleId IdType="pubmed">29316653</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Fotinos A., Wu Q., Chen Y., Zhu Y., Baranov S., Tu Y., Zhou E.W., Sinha B., Kristal B.S., et al. N-acetyl-L-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model. Neurobiol. Dis. 2015;80:93&#x2013;103. doi: 10.1016/j.nbd.2015.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.05.002</ArticleId><ArticleId IdType="pubmed">25986728</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen E.C. The role of neurotrophic factors in disorders of peripheral nerves and motor neurons. Phys. Med. Rehabil. Clin. N. Am. 2001;12:293&#x2013;306. doi: 10.1016/S1047-9651(18)30070-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1047-9651(18)30070-6</ArticleId><ArticleId IdType="pubmed">11345008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shruthi S., Sumitha R., Varghese A.M., Ashok S., Chandrasekhar Sagar B.K., Sathyaprabha T.N., Nalini A., Kramer B.W., Raju T.R., Vijayalakshmi K., et al. Brain-Derived Neurotrophic Factor Facilitates Functional Recovery from ALS-Cerebral Spinal Fluid-Induced Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line. Neurodegener. Dis. 2017;17:44&#x2013;58. doi: 10.1159/000447559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000447559</ArticleId><ArticleId IdType="pubmed">27617773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Klinkosz B., Greene T., Cedarbaum J.M., Wong V., Lindsay R.M., Mitsumoto H. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. 1995;37:505&#x2013;511. doi: 10.1002/ana.410370413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410370413</ArticleId><ArticleId IdType="pubmed">7717687</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao C.C., Ma Y.L., Lee E.H. Brain-derived neurotrophic factor enhances Bcl-xL expression through protein kinase casein kinase 2-activated and nuclear factor kappa B-mediated pathway in rat hippocampus. Brain Pathol. 2011;21:150&#x2013;162. doi: 10.1111/j.1750-3639.2010.00431.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2010.00431.x</ArticleId><ArticleId IdType="pmc">PMC8094249</ArticleId><ArticleId IdType="pubmed">20731656</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervetto C., Frattaroli D., Maura G., Marcoli M. Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism. Toxicology. 2013;311:69&#x2013;77. doi: 10.1016/j.tox.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2013.04.004</ArticleId><ArticleId IdType="pubmed">23583883</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivan S., Calvo A.C., Rando A., Munoz M.J., Zaragoza P., Osta R. Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Exp. Anim. 2015;64:147&#x2013;153. doi: 10.1538/expanim.14-0077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1538/expanim.14-0077</ArticleId><ArticleId IdType="pmc">PMC4427729</ArticleId><ArticleId IdType="pubmed">25736480</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves C.J., de Santana L.P., dos Santos A.J., de Oliveira G.P., Duobles T., Scorisa J.M., Martins R.S., Maximino J.R., Chadi G. Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Res. 2011;1394:90&#x2013;104. doi: 10.1016/j.brainres.2011.02.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.02.060</ArticleId><ArticleId IdType="pubmed">21354109</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.I., Lee Y.D., Gwag B.J., Cho S.I., Kim S.S., Suh-Kim H. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J. Neurol. Sci. 2008;268:40&#x2013;47. doi: 10.1016/j.jns.2007.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.10.024</ArticleId><ArticleId IdType="pubmed">18054961</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J.P.K., Visser A.E., D&#x2019;Ovidio F., Vermeulen R., Beghi E., Chio A., Veldink J.H., Logroscino G., van den Berg L.H., Hardiman O., et al. A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR. Neurology. 2017;89:1283&#x2013;1290. doi: 10.1212/WNL.0000000000004390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004390</ArticleId><ArticleId IdType="pubmed">28835399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y.X., Zhao M., Liu Y.L., Chen L.S., Hao P.L., Sun C. Expression of aromatase and estrogen receptors in lumbar motoneurons of mice. Neurosci. Lett. 2017;653:7&#x2013;11. doi: 10.1016/j.neulet.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.05.017</ArticleId><ArticleId IdType="pubmed">28501695</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasem R.J. The estrogenic activity of resveratrol: A comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit. Rev. Toxicol. 2020;50:439&#x2013;462. doi: 10.1080/10408444.2020.1762538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408444.2020.1762538</ArticleId><ArticleId IdType="pubmed">32744480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajializadeh Z., Khaksari M. The protective effects of 17-beta estradiol and SIRT1 against cardiac hypertrophy: A review. Heart Fail. Rev. 2021 doi: 10.1007/s10741-021-10171-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-021-10171-0</ArticleId><ArticleId IdType="pubmed">34537933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y., Li H., Gu Y., Davidson N.E., Zhou Q. Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis. 2010;31:382&#x2013;387. doi: 10.1093/carcin/bgp308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgp308</ArticleId><ArticleId IdType="pmc">PMC2832546</ArticleId><ArticleId IdType="pubmed">19995796</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.M., Shu H., Wang L., Xu J.J., Niu X.C., Zhang L. SIRT1-dependent AMPK pathway in the protection of estrogen against ischemic brain injury. CNS Neurosci. Ther. 2017;23:360&#x2013;369. doi: 10.1111/cns.12686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12686</ArticleId><ArticleId IdType="pmc">PMC6492707</ArticleId><ArticleId IdType="pubmed">28256111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabadiya S., Bhadada S., Dudhrejiya A., Vaishnav D., Patel B. Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. Biomed. Pharmacother. 2018;97:919&#x2013;927. doi: 10.1016/j.biopha.2017.10.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.10.137</ArticleId><ArticleId IdType="pubmed">29136770</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortunati N., Bertino S., Costantino L., De Bortoli M., Compagnone A., Bandino A., Catalano M.G., Boccuzzi G. Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells. Mol. Cell Endocrinol. 2010;314:17&#x2013;22. doi: 10.1016/j.mce.2009.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2009.09.011</ArticleId><ArticleId IdType="pubmed">19772891</ArticleId></ArticleIdList></Reference><Reference><Citation>Stettner M., Kaulfuss S., Burfeind P., Schweyer S., Strauss A., Ringert R.H., Thelen P. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol. Cancer Ther. 2007;6:2626&#x2013;2633. doi: 10.1158/1535-7163.MCT-07-0197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-07-0197</ArticleId><ArticleId IdType="pubmed">17913855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004;20:3179&#x2013;3183. doi: 10.1111/j.1460-9568.2004.03765.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03765.x</ArticleId><ArticleId IdType="pubmed">15579172</ArticleId></ArticleIdList></Reference><Reference><Citation>Crochemore C., Virgili M., Bonamassa B., Canistro D., Pena-Altamira E., Paolini M., Contestabile A. Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve. 2009;39:548&#x2013;552. doi: 10.1002/mus.21260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21260</ArticleId><ArticleId IdType="pubmed">19296491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouaux C., Panteleeva I., Rene F., Gonzalez de Aguilar J.L., Echaniz-Laguna A., Dupuis L., Menger Y., Boutillier A.L., Loeffler J.P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 2007;27:5535&#x2013;5545. doi: 10.1523/JNEUROSCI.1139-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1139-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672753</ArticleId><ArticleId IdType="pubmed">17522299</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepers S., Veldink J.H., de Jong S.W., van der Tweel I., van der Pol W.L., Uijtendaal E.V., Schelhaas H.J., Scheffer H., de Visser M., de Jong J.M., et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 2009;66:227&#x2013;234. doi: 10.1002/ana.21620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21620</ArticleId><ArticleId IdType="pubmed">19743466</ArticleId></ArticleIdList></Reference><Reference><Citation>Markert C.D., Kim E., Gifondorwa D.J., Childers M.K., Milligan C.E. A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J. Med. Food. 2010;13:1081&#x2013;1085. doi: 10.1089/jmf.2009.0243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jmf.2009.0243</ArticleId><ArticleId IdType="pubmed">20626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S., Choi J.R., Soon Shin K., Kang S.J. Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Res. 2012;1483:112&#x2013;117. doi: 10.1016/j.brainres.2012.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.09.022</ArticleId><ArticleId IdType="pubmed">23000195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Rayner S., Chung R., Shi B., Liang X. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Mater. Today Bio. 2020;6:100055. doi: 10.1016/j.mtbio.2020.100055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2020.100055</ArticleId><ArticleId IdType="pmc">PMC7280770</ArticleId><ArticleId IdType="pubmed">32529183</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova A., Angelov B. Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair. Neural Regen. Res. 2017;12:886&#x2013;889. doi: 10.4103/1673-5374.208546.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.208546</ArticleId><ArticleId IdType="pmc">PMC5514857</ArticleId><ArticleId IdType="pubmed">28761415</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., Pitzer C., Schneider A. Characterization of a novel SOD-1(G93A) transgenic mouse line with very decelerated disease development. PLoS ONE. 2010;5:e15445. doi: 10.1371/journal.pone.0015445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015445</ArticleId><ArticleId IdType="pmc">PMC2978730</ArticleId><ArticleId IdType="pubmed">21102999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>